Tuesday, June 6, 2017
- 1:45pm-3:15pm
-
Analysis of serum non-mercaptoalbumin in patients with Parkinson’s disease
Parkinson's Disease: Pathophysiology · Exhibit Hall C
- 1:45pm-3:15pm
-
Anti-synuclein alpha antibodies and IL-1β at Parkinson Disease (PD).
Parkinson's Disease: Pathophysiology · Exhibit Hall C
- 1:45pm-3:15pm
-
Antibody binding differences in alpha-synuclein from Parkinson’s disease and multiple system atrophy
Parkinson's Disease: Pathophysiology · Exhibit Hall C
- 1:45pm-3:15pm
-
Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity
Therapy in Movement Disorders · Exhibit Hall C
- 1:45pm-3:15pm
-
Antisense oligonucleotides containing amido-bridged nucleic acid downregulate SNCA expression and improve motor function in Parkinson’s disease mouse models.
Therapy in Movement Disorders · Exhibit Hall C
- 1:45pm-3:15pm
-
Ascertainment of Impaired Balance in Orthostatic Tremor Patients
Tremor · Exhibit Hall C
- 1:45pm-3:15pm
-
Assessing Parkinson’s disease motor symptoms using supervised learning algorithms
Technology · Exhibit Hall C
- 1:45pm-3:15pm
-
Assessment of graphomotor impairment in patients with Spinocerebellar ataxia and Parkinson’s disease
Technology · Exhibit Hall C
- 1:45pm-3:15pm
-
Assessment of neurodegeneration and spreading of α-synuclein pathology induced by structurally defined α-synuclein assemblies in wild-type mice
Parkinson's Disease: Pathophysiology · Exhibit Hall C
- 1:45pm-3:15pm
-
Assessment of new technology in deep brain stimulation technology: what are the anticipated benefits?
Technology · Exhibit Hall C
- «Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 38
- Next Page»